Howard Berman is an accomplished biotech entrepreneur and board member with over 25 years of leadership experience across public and private life sciences companies. He is the Executive Chairman and Chairman of the Board of Coya Therapeutics (Nasdaq: COYA), a company he founded from a concept in 2020 and served as Chief Executive Officer, guiding it through its IPO in 2023 and subsequent market appreciation in one of the most challenging biotech environments. He also founded Imaware, Inc., successfully leading it through a strategic M&A acquisition in 2024. In addition, Dr. Berman serves on the Board of Directors of Atea Pharmaceuticals (Nasdaq: AVIR).

Earlier in his career, Dr. Berman held management and clinical development roles at leading global biopharmaceutical companies including Novartis, Eli Lilly, AbbVie, and Morphosys, where he contributed to the development and launch of multiple blockbuster drugs such as Focalin XR®, Alimta®, Monjuvi®, and Venclexta®.

A recognized innovator, Dr. Berman has raised over $100M in venture, public, and non-dilutive funding, built companies advancing novel biologics, platform technologies, and digital health solutions, and signed strategic pharmaceutical transactions valued at nearly $1 billion, while forging partnerships with industry leaders. His therapeutic focus spans oncology, CNS and neurodegeneration, inflammation, and metabolic diseases.

He is known for his ability to navigate capital markets, engage institutional investors, and execute corporate transactions while leveraging deep expertise in cancer biology, pharmacology, immunology, and clinical development.